Immune Thrombocytopenia natural history, complications and prognosis
Immune Thrombocytopenia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Immune Thrombocytopenia natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Immune Thrombocytopenia natural history, complications and prognosis |
FDA on Immune Thrombocytopenia natural history, complications and prognosis |
CDC on Immune Thrombocytopenia natural history, complications and prognosis |
Immune Thrombocytopenia natural history, complications and prognosis in the news |
Blogs on Immune Thrombocytopenia natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Barkhordarian, M.D.[2]
Overview
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
OR
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
OR
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
Natural History, Complications, and Prognosis
Natural History
- The symptoms of chronic immune thrombocytopenia usually develop in the any decade of life, many patients are asymptomatic however about two third of patients start with symptoms such as mucocutaneous , gastrointestinal and genitourinary bleeding.[1][2]
- The symptoms of (disease name) typically develop ___ years after exposure to ___.
- If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
Complications
- Common complications of [disease name] include:
- [Complication 1]
- [Complication 2]
- [Complication 3]
Prognosis
- Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [--]%.
- Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
- The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
- [Subtype of disease/malignancy] is associated with the most favorable prognosis.
- The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.
References
- ↑ . doi:10.2147/JBM.S289390. Check
|doi=
value (help). Missing or empty|title=
(help) - ↑ Kohli, Rahil; Chaturvedi, Shruti (2019). "Epidemiology and Clinical Manifestations of Immune Thrombocytopenia". Hämostaseologie. 39 (03): 238–249. doi:10.1055/s-0039-1683416. ISSN 0720-9355.